European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Authors
Keywords
Cutaneous melanoma, Tumor thickness, Excisional margins, Sentinel lymph node dissection, Interferon-α, Adjuvant treatment, Metastasectomy, Systemic treatment
Journal
EUROPEAN JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-05-24
DOI
10.1016/j.ejca.2022.04.018
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Surgical excision margins in primary cutaneous melanoma: A systematic review and meta-analysis
- (2021) Sarah Hanna et al. EJSO
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis
- (2021) Omid Ahmadi et al. ANNALS OF SURGICAL ONCOLOGY
- Real‐world experience on off‐label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna
- (2021) A. Lallas et al. BRITISH JOURNAL OF DERMATOLOGY
- Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
- (2021) Ines Pires da Silva et al. LANCET ONCOLOGY
- 1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047
- (2021) F.S. Hodi et al. ANNALS OF ONCOLOGY
- Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection
- (2021) Robert J. Torphy et al. ANNALS OF SURGICAL ONCOLOGY
- 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
- (2021) Paolo A. Ascierto et al. CLINICAL CANCER RESEARCH
- Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
- (2021) Georgina V. Long et al. CLINICAL CANCER RESEARCH
- Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.
- (2021) Rodabe Navroze Amaria et al. JOURNAL OF CLINICAL ONCOLOGY
- Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
- (2021) Alexander M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.
- (2021) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).
- (2021) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.
- (2021) Celeste Lebbe et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.
- (2021) Ana Maria Arance et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.
- (2021) Victoria Atkinson et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
- (2021) Jedd D. Wolchok et al. JOURNAL OF CLINICAL ONCOLOGY
- Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
- (2021) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review
- (2021) Yi Ge et al. MELANOMA RESEARCH
- Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis
- (2021) Kenneth K. Cho et al. MELANOMA RESEARCH
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
- (2021) Lars Ny et al. Nature Communications
- Molecular Markers and Targets in Melanoma
- (2021) Cristina Teixido et al. Cells
- Radiation Therapy for Brain Metastases: A Systematic Review
- (2021) Adam Garsa et al. Practical Radiation Oncology
- Systematic Review of Technical Variations for Mohs Micrographic Surgery for Melanoma
- (2021) Aimee E. Krausz et al. DERMATOLOGIC SURGERY
- Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis
- (2021) Simone M. Goldinger et al. EUROPEAN JOURNAL OF CANCER
- DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.
- (2021) Michael B. Atkins et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
- (2020) Paolo A. Ascierto et al. EUROPEAN JOURNAL OF CANCER
- Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
- (2020) C.N. Owen et al. ANNALS OF ONCOLOGY
- Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy
- (2020) Norma E. Farrow et al. ANNALS OF SURGICAL ONCOLOGY
- A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
- (2020) Mallika Lala et al. EUROPEAN JOURNAL OF CANCER
- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
- (2020) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD.
- (2020) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
- (2020) Alexander M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate 067: Long-term outcomes in patients with mucosal melanoma.
- (2020) Alexander Noor Shoushtari et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Lisa Zimmer et al. LANCET
- Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
- (2020) Teresa Amaral et al. Journal for ImmunoTherapy of Cancer
- Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
- (2020) Teresa Amaral et al. Cancers
- Ano-uro-genital mucosal melanoma UK national guidelines
- (2020) Henry G. Smith et al. EUROPEAN JOURNAL OF CANCER
- Head and neck mucosal melanoma: The United Kingdom national guidelines
- (2020) Pablo Nenclares et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
- (2020) Franz J. Hilke et al. Cancers
- Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
- (2020) Qingyue Zheng et al. Frontiers in Oncology
- Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis
- (2019) Giulia Galli et al. Oncology Research and Treatment
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
- (2019) Celeste Lebbé et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases
- (2019) Ricarda Rauschenberg et al. EUROPEAN JOURNAL OF CANCER
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).
- (2019) Maria Gonzalez et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
- (2019) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
- (2019) Ulrike Leiter et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
- (2019) Markus V. Heppt et al. Journal for ImmunoTherapy of Cancer
- Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update
- (2018) Sandra L. Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2018) Michele Maio et al. LANCET ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
- (2018) G V Long et al. ANNALS OF ONCOLOGY
- A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.
- (2018) Mallika Lala et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.
- (2018) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma
- (2018) Dirk Schadendorf et al. LANCET
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data
- (2018) Eric J. Lehrer et al. RADIOTHERAPY AND ONCOLOGY
- LBA47Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
- (2018) C Lebbé et al. ANNALS OF ONCOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection
- (2018) Thomas M. Churilla et al. JAMA Oncology
- A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures
- (2017) D. Tio et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
- (2017) Paul D Brown et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial
- (2017) Anita Mahajan et al. LANCET ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- (2017) Mark B. Faries et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correlation of Handheld Reflectance Confocal Microscopy With Radial Video Mosaicing for Margin Mapping of Lentigo Maligna and Lentigo Maligna Melanoma
- (2017) Oriol Yélamos et al. JAMA Dermatology
- Evaluation of dosing strategy for pembrolizumab for oncology indications
- (2017) Tomoko Freshwater et al. Journal for ImmunoTherapy of Cancer
- 1130TiPNEMO: A PHASE 3 TRIAL OF BINIMETINIB (MEK162) VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA WHO ARE UNTREATED OR HAVE PROGRESSED AFTER ANY NUMBER OF IMMUNOTHERAPY REGIMENS
- (2017) R. Dummer et al. ANNALS OF ONCOLOGY
- Melanoma
- (2017) Daniel G. Coit et al. Journal of the National Comprehensive Cancer Network
- Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma
- (2017) Maria Rita Gaiser et al. PLoS One
- Sentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis
- (2016) Erin Cordeiro et al. ANNALS OF SURGICAL ONCOLOGY
- Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision
- (2016) K. de Vries et al. BRITISH JOURNAL OF DERMATOLOGY
- Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation
- (2016) Keith Wheatley et al. CANCER TREATMENT REVIEWS
- Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial
- (2016) Andrew J Hayes et al. LANCET ONCOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
- (2016) Ulrike Leiter et al. LANCET ONCOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Uveal Melanoma UK National Guidelines
- (2015) P. Nathan et al. EUROPEAN JOURNAL OF CANCER
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type
- (2015) Susan M. Swetter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial
- (2015) Michael A Henderson et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
- (2015) Jean Jacques Grob et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
- (2015) Marka Crittenden et al. SEMINARS IN RADIATION ONCOLOGY
- On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases
- (2014) C. Gaudy-Marqueste et al. ANNALS OF ONCOLOGY
- Treatment of Lentigo Maligna with Imiquimod before Staged Excision
- (2014) MURRAY A. COTTER et al. DERMATOLOGIC SURGERY
- Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
- (2014) Antoni Ribas et al. LANCET ONCOLOGY
- Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
- (2014) Donald L. Morton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
- (2014) Antonio M Grimaldi et al. OncoImmunology
- Cutaneous melanoma
- (2013) Alexander MM Eggermont et al. LANCET
- Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
- (2012) B Weide et al. BRITISH JOURNAL OF CANCER
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial
- (2012) Bryan H Burmeister et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
- (2011) Jan P. Deroose et al. ANNALS OF SURGICAL ONCOLOGY
- Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
- (2011) Poulam M. Patel et al. EUROPEAN JOURNAL OF CANCER
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Does metastasectomy improve survival in patients with stage IV melanoma? a cancer registry analysis of outcomes
- (2011) Nabil Wasif et al. JOURNAL OF SURGICAL ONCOLOGY
- 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial
- (2011) Peter Gillgren et al. LANCET
- Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
- (2011) Johan Hansson et al. LANCET ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma
- (2010) A. Y. Bedikian et al. ANNALS OF ONCOLOGY
- Revised U.K. guidelines for the management of cutaneous melanoma 2010
- (2010) J.R. Marsden et al. BRITISH JOURNAL OF DERMATOLOGY
- Incisional biopsy and melanoma prognosis: Facts and controversies
- (2010) Annette Pflugfelder et al. CLINICS IN DERMATOLOGY
- A new era: melanoma genetics and therapeutics
- (2010) Justin M Ko et al. JOURNAL OF PATHOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting
- (2009) Claus Garbe et al. MELANOMA RESEARCH
- Adjuvant low-dose interferon 2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
- (2008) C. Garbe et al. ANNALS OF ONCOLOGY
- Topical Imiquimod Therapy for Lentigo Maligna
- (2008) Mary-Helen Mahoney et al. ANNALS OF PLASTIC SURGERY
- Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients
- (2008) Urs V. Buettiker et al. ARCHIVES OF DERMATOLOGY
- Surgery for melanoma metastases of the gastrointestinal tract: Indications and results
- (2008) A. Sanki et al. EJSO
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started